Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07043270 · ClinicalTrials.gov registry record · Phase 2
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
A Phase 2 study of Pancreas Adenocarcinoma, sponsored by Dartmouth-Hitchcock Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT07043270: Recruiting Phase 2 study of Pancreas Adenocarcinoma, sponsored by Dartmouth-Hitchcock Medical Center.
NCT07043270 is a Phase 2 study of Pancreas Adenocarcinoma that is actively recruiting participants, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 35 participants, below the 76-participant average among 10 other Pancreas Adenocarcinoma trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07043270, a Phase 2 study of Pancreas Adenocarcinoma, is actively recruiting participants, sponsored by Dartmouth-Hitchcock Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.
Primary Outcome
One-year EFS is defined as completing one year from enrollment without the occurrence of any of the following events: 1) disease progression per Response Evaluation Criteria in Solid Tumors (RECIST), 2) surgery with R2 resection, 3) recurrent disease following surgery, or 4) death from any cause.
Conditions Studied
Interventions
- DRUG Nab-paclitaxel + Gemcitabine
- DRUG modified FOLFIRINOX (mFOLFIRINOX)
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2029-07-01 |
| Phase | Phase 2 |
What NCT07043270 shows while recruiting
NCT07043270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 76-participant average among 10 other Pancreas Adenocarcinoma trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Pancreas Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Nab-paclitaxel + Gemcitabine is the first listed.
NCT07043270 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT07043270 about?
NCT07043270 is a clinical study titled "24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC". The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.
What is the current status of trial NCT07043270?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-09-29. Estimated completion is 2029-07-01.
What conditions does trial NCT07043270 study?
This clinical trial studies the following conditions: Pancreas Adenocarcinoma.
What interventions are being tested in trial NCT07043270?
The interventions under investigation include: Nab-paclitaxel + Gemcitabine (DRUG), modified FOLFIRINOX (mFOLFIRINOX) (DRUG).
Who is sponsoring clinical trial NCT07043270?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07043270 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07043270's enrollment target sits among peer trials
35 7th of 10 higher than 4 of 10 other Pancreas Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
RECRUITING · Phase 2
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
RECRUITING · Phase 2
-
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
ACTIVE NOT RECRUITING · Phase 2
-
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI